MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7% – Still a Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s share price rose 0.7% during trading on Tuesday . The company traded as high as $1.5861 and last traded at $1.50. Approximately 1,222,219 shares were traded during trading, an increase of 4% from the average daily volume of 1,180,232 shares. The stock had previously closed at $1.49.

MAIA Biotechnology Price Performance

The stock has a 50 day simple moving average of $1.94 and a two-hundred day simple moving average of $1.58. The company has a market cap of $57.99 million, a price-to-earnings ratio of -2.05 and a beta of -0.04.

Insider Transactions at MAIA Biotechnology

In other news, Director Stan Smith acquired 57,189 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, with a total value of $69,770.58. Following the completion of the acquisition, the director owned 1,421,478 shares of the company’s stock, valued at $1,734,203.16. This trade represents a 4.19% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ngar Yee Louie acquired 81,699 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, with a total value of $99,672.78. Following the completion of the transaction, the director owned 1,248,888 shares of the company’s stock, valued at $1,523,643.36. The trade was a 7.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 179,737 shares of company stock worth $219,279 in the last quarter. Company insiders own 32.32% of the company’s stock.

Institutional Trading of MAIA Biotechnology

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the last quarter. Centric Wealth Management lifted its holdings in MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Marshall Wace LLP purchased a new position in MAIA Biotechnology in the second quarter worth approximately $29,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology in the second quarter worth approximately $52,000. Finally, Ritholtz Wealth Management acquired a new stake in MAIA Biotechnology during the fourth quarter worth $35,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.